Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sunesis Pharmaceuticals has commenced patient treatment in a phase I trial of SNS-032, an anticancer agent in-licensed from Bristol-Myers Squibb in April 2005.
Subscribe to our email newsletter
The trial is designed to examine the safety and preliminary anti-tumor activity of SNS-032 and will enroll patients with advanced solid tumor cancers. Once a maximum-tolerated dose has been identified, enrollment will expand by 24 patients with lung cancer, breast cancer or melanoma. Patients will be enrolled at three centers in the US.
SNS-032 is a novel small molecule inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9. This is the company’s second anticancer cell-cycle inhibitor to enter clinical trials.
“In preclinical studies, SNS-032 demonstrated anti-tumor activity in multiple solid and hematological tumor models. We believe that CDKs 2, 7 and 9 are promising therapeutic targets for cancer therapy and we are hopeful that SNS- 032 will prove to be a safe an efficacious novel cancer treatment,” said Dan Swisher, CEO of Sunesis.